ReviewFrontiers in physiology2020
Immune and Apoptosis Mechanisms Regulating Placental Development and Vascularization in Preeclampsia.
Review in Frontiers in physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- Association between maternal depressive symptoms during pregnancy and the risk of preeclampsia: a meta-analysis.Frontiers in psychiatry · 2026Pooled it
- Maternal opioid use and hepatitis C infection disrupt the placental immune landscape and structure.JCI insight · 2026Article
- The Impact of Fetal Growth Restriction on Myocardial Development from Fetal Life to Early Childhood: A Narrative Review.Children (Basel, Switzerland) · 2026Review
- Article
- Altered Expression of Calpastatin by Hypoxia Regulates Trophoblast Cell Function through Mitochondria Associated Endoplasmic Reticulum Membranes.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Comparison of Sub-foveal Choroidal Thickness in Patients with Hypertensive Disorders of Pregnancy Versus Normotensive Pregnant Women in Third Trimester.Journal of obstetrics and gynaecology of India · 2025Article
- Maternal opioid use with and without hepatitis C infection disrupts the structure and immune landscape of the maternal-fetal interface.bioRxiv : the preprint server for biology · 2025Article
- Systemic and Local Immunological Markers in Preeclampsia.Diagnostics (Basel, Switzerland) · 2025Article
- p53-mediated suppression of the SLC7 A11/GPX4 signaling pathway promotes trophoblast ferroptosis in preeclampsia.BMC biology · 2025Article
- Immunomodulatory effect of efferocytosis at the maternal-fetal interface.Cell communication and signaling : CCS · 2025Review
- Modeling human placental biology: a review of organoid technologies.Frontiers in cell and developmental biology · 2025Review
- Expression of Properdin, the positive regulator of the Complement Alternative Pathway, at the fetal-maternal interface in Preeclampsia.Frontiers in immunology · 2025Article
- Using weighted gene co-expression network analysis to identify key genes related to preeclampsia.Frontiers in immunology · 2025Article
- Nutraceuticals as Modulators of Molecular Placental Pathways: Their Potential to Prevent and Support the Treatment of Preeclampsia.International journal of molecular sciences · 2024Review
- Antioxidant Defenses, Oxidative Stress Responses, and Apoptosis Modulation in Spontaneous Abortion: An Immunohistochemistry Analysis of First-Trimester Chorionic Villi.Life (Basel, Switzerland) · 2024Article
- A Narrative Review on the Pathophysiology of Preeclampsia.International journal of molecular sciences · 2024Review
- TGFβ signalling: a nexus between inflammation, placental health and preeclampsia throughout pregnancy.Human reproduction update · 2024Review
- Diagnosis, Prevention, and Management of Fetal Growth Restriction (FGR).Journal of personalized medicine · 2024Review
- The Role of Catestatin in Preeclampsia.International journal of molecular sciences · 2024Review
- Diagnostic significance of blood lymphocyte activation markers in pre-eclampsia.Clinical and experimental immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia is the most severe type of hypertensive disorder of pregnancy, affecting one in 10 pregnancies worldwide and increasing significantly maternal and neonatal morbidity and mortality. Women developing preeclampsia display an array of symptoms encompassing uncontrolled hypertension and proteinuria, with neurological symptoms including seizures at the end of pregnancy. The main causes of preeclampsia are still unknown. However, abnormal placentation and placenta vascularization seem to be common features in preeclampsia, also leading to fetal growth restriction mainly due to reduced placental blood flow and chronic hypoxia. An over activation of maternal immunity cells against the trophoblasts, the main cells forming the placenta, has been recently shown as an important mechanism triggering trophoblast apoptosis and death. This response will further disrupt the remodeling of maternal uterine arteries, in a first stage, and the formation of new placental vessels in a later stage. A consequent chronic hypoxia stress will further contribute to increase placental stress and exacerbate systemic circulatory changes in the mother. The molecular mechanisms driving these processes of apoptosis and anti-angiogenesis are also not well-understood. In this review, we group main evidences suggesting potential targets and molecules that should be better investigated in preeclampsia. This knowledge will contribute to improve therapies targeting a better placenta formation, having a positive impact on maternal disease prevention and on fetal development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.